Medimmune Limited

Steven Rust

Ralph Raymond Minter

Charles K Stover

Sandrine Guillard

Antonio Digiandomenico

Paul Warrener

Mladen Tomich

Bret Sellman

Changshou Gao

Partha S Chowdhury

Nazzareno Dimasi

Ryan Fleming

Melissa Marie Damschroder

Scott A Hammond

Reena Varkey

Godfrey Rainey

Michael A Bowen

Carl Hay

Ching Ching Leow

Cuihua Gao

Peter Pavlik

Robert E Hollingsworth

Kris Sachsenmeier

Erin Sult

Brett R Sellman

Nicholas Durham

Binyam Bezabeh

Jonathan Rios-Doria

Kim Rosenthal

Xiaojun Lu

James Geoghegan

Mary Antonysamy

Li Cheng

Qihui Huang

Vignesh Venkatraman

Li Peng

Elaine M Hurt

Gundo Diedrich

Julie Ann Douthwaite

Cyril V Privezentzev

Alan Sandercock

Sotirios Karathanasis

Jacques Moisan

Paul G Warrener

Ralph Minter

Julie Douthwaite

Michael Bowen

Cyril Privesentzev

This disclosure relates to combination therapies comprising anti-Psl and PcrV binding molecules and related compositions, for use in prevention and treatment ofinfection.

Combination therapies using anti-pseudomonas PSL and PCRV binding molecules

This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind toPcrV as well as vectors and host cells comprising the same.

Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv

The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.

Compositions and methods for inhibiting cancer stem cells

This disclosure relates to an anti-Psl binding molecule and uses thereof, in particular in prevention and treatment ofinfection. Furthermore, the disclosure provides compositions and methods for preventing and treatinginfection.

Anti-Psl binding molecules and uses thereof

The disclosure relates to an anti-PSL binding molecule and uses thereof, in particular, in prevention and treatment ofinfection. Furthermore, the disclosure provides compositions and methods for preventing and treatinginfection.

Anti-pseudomonas Psl binding molecules and uses thereof

Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.

CTLA-4 variants

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.

Multispecific and multivalent binding proteins and uses thereof

Growing community of inventors

Cambridge, United Kingdom

Steven Rust